Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 397 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of ‘Low-Alcohol’ Labelling in Response to the Council Agreement on the EU’s Wine Package MOST POPULAR New Research in Treating Leukemia and Lymphoma: ASH Annual Meeting 2020 January 15, 2021 Simple Hysterectomy May Expand Treatment Options for Early-Stage Cervical Cancer March 27, 2024 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... September 10, 2024 ESMO awards its first fellowship to support digital and computational pathology September 10, 2025 Load more HOT NEWS Coronavirus reports: “As a Black man with advanced prostate cancer, who... Aiming to Prevent Cancer Cases, ESMO Campaigns Against the Use of... 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Multiple... Football Player Scores 8 Touchdowns the Day After His Mom Dies...
